Ondine Biomedical Inc. (AIM:OBI)
London · Delayed Price · Currency is GBP · Price in GBX 12.75
-0.25 (-1.92%)
Aug 8, 2025, 4:35 PM GMT+1
Ondine Biomedical Company Description
Ondine Biomedical Inc., a life-sciences company, engages in the development and commercialization of antimicrobial therapies in Canada and internationally.
Its primary product is Steriwave, which enables rapid elimination of pathogens associated with healthcare-associated infections.
In addition, the company offers a pipeline of products for various indications, including burns, ventilator tube, and sinus; and serious and chronic wounds, chronic sinusitis, ventilator-associated pneumonia VAP, and central line bloodstream infections, as well as catheter-associated urinary tract infection.
Ondine Biomedical Inc. was incorporated in 1996 and is headquartered in Vancouver, Canada.
Ondine Biomedical Inc.
| Country | Canada |
| Founded | 1996 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 18 |
| CEO | Carolyn Cross |
Contact Details
Address: 1100 Melville Street Vancouver, British Columbia V6E 4A6 Canada | |
| Phone | 604 669 0555 |
| Website | ondinebio.com |
Stock Details
| Ticker Symbol | OBI |
| Exchange | London Stock Exchange AIM |
| Fiscal Year | January - December |
| Reporting Currency | CAD |
| ISIN Number | CA68234M2058 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Carolyn Cross | Chief Executive Officer |
| Alan Thomas | Chief Financial Officer |